ProPublica

Journalism in the Public Interest

Cancel

Pharma Company Disclosures

Beginning in 2014, the Physician Payment Sunshine Act requires every pharmaceutical and medical device company to publicly report payments to physicians. Before those disclosures started, however, a number of companies released details of their financial relationships with physicians, and sometimes other health providers. Most of these companies (or one of their subsidiaries) were required to disclose under corporate integrity agreements with the Inspector General of the U.S. Department of Health and Human Services. We are displaying what companies disclosed in 2013.

Company Required to Disclose? First Disclosure
Year
Speaking fees
Consulting fees
Research
Travel fees
Meals
Educational Items/Gifts
Royalty or License Fees
AbbVie x 2012
Allergan x 2010
Amgen x 2013
AstraZeneca x 2010
Boehringer Ingelheim x 2013
Cephalon * 2009
Eli Lilly x 2009
EMD Serono * 2011
Forest x 2012
GlaxoSmithKline * 2009
Johnson & Johnson x 2010
Merck * 2009
Novartis x 2010
Pfizer x 2009
UCB x 2012
Valeant x 2010
ViiV 2010

Notes:

  • GlaxoSmithKline and Merck began disclosing voluntarily in 2009 but later agreed to do so as a condition of a legal settlement with the U.S. government.
  • AbbVie combines all categories into a single amount and does not break out specific spending on each category.
  • Allergan first reported payments in 2010 but later removed some payments from its website. Those payments are not included in this database. Allergan also reports in ranges and does not break out specific spending on each category.
  • Cephalon pulled its disclosures offline in early 2014 because its Corporate Integrity Agreement with the HHS inspector general had expired. The data on this site reflects payments disclosed from 2009 to the second quarter of 2013.
  • EMD Serono pulled its disclosures offline in September 2014 because its Corporate Integrity Agreement with the HHS inspector general had expired. This data on this site reflects payments disclosed from 2011 to 2013.
  • Johnson & Johnson's report includes the payments disclosed separately by four of its subsidiaries.
  • Lilly combines business travel and educational items/gifts in one category and does not break apart the value of each.
  • Novartis changed its reporting period from fiscal year to calendar year, so there is no data displayed for Q4 2011.
  • UCB combines all categories into a single amount and does not break out specific spending on each category.